Skip to main content
Clinical Trials/NCT02042768
NCT02042768
Completed
Not Applicable

An Investigation of the Effects of Different Dialysis Prescriptions on Systemic Glucose Metabolism and Mortality in Non-diabetic Peritoneal Dialysis Patients

Keele University1 site in 1 country1,451 target enrollmentMarch 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Glucose Metabolism Disorders
Sponsor
Keele University
Enrollment
1451
Locations
1
Primary Endpoint
Mortality
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

Peritoneal Dialysis (PD) is a commonly used treatment for end stage renal failure, and the most commonly used dialysate contains unphysiological amounts of glucose, a high proportion of which is absorbed. Recent analysis of the Global Fluid Study, has established that in non-diabetic prevalent patients on PD a random glucose level is dependent on dialysate glucose load and is a predictor of death. By utilising clinical data and additional biosamples collected for the NIHR funded PD-CRAFT study, the investigators aim to confirm this finding, define the relationship between dialysate glucose exposure according to prescription regimes and glycaemia, define the most useful biomarker to monitor glycaemia , and establish the role that impaired insulin sensitivity plays in blood glucose levels. Furthermore the investigators will explore the hypothesis that insulin resistance is associated with disturbance of the carnitine/acetyl-carnitine equilibrium that might benefit from intra-peritoneal carnitine supplementation.

PD-CRAFT is an observational cohort study of 3000 prevalent PD patients collecting detailed clinical data, including glucose exposure and samples of dialysate. and blood which will be stored in the UK BioCentre. Follow up is for up to 2 years or endpoint (death, technique failure).

Multivariate regression will be used to establish determinants of the non-fasting blood glucose and other measures of glycaemia, in particular different dialysis regimes, (e.g. modality, dwell lengths, fill volumes, and dialysate type and concentration specifically seeking to identify prescriptions that minimise the systemic effects) combined with measures of insulin resistance. The investigators will establish whether blood glucose predicts survival in an adjusted analysis (~300 endpoints needed) using Cox regression and explore the relationship of other biomarkers to survival.

Registry
clinicaltrials.gov
Start Date
March 2013
End Date
December 31, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • On peritoneal dialysis

Exclusion Criteria

  • Not providing informed consent.
  • Diabetes.

Outcomes

Primary Outcomes

Mortality

Time Frame: Patients will be followed up for the duration of the study period, an expected average of 24 months

From study entry to date of death from any cause, assessed up to June 2015

Secondary Outcomes

  • Cardiovascular mortality(Patients will be followed up for the duration of the study period, an expected average of 24 months)

Study Sites (1)

Loading locations...

Similar Trials